Physician profile
Robert C Ward
NPI 1598762379
$1,525.96
in general payments reported to CMS, 2019-2025
31 companies · $245 in 2025
The $245 reported for 2025 was less than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $294 · 2020: $81.96 · 2021: $196 · 2022: $185 · 2023: $237 · 2024: $287 · 2025: $245.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $751 · Education: $17.90.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $750.85 |
| Education | $17.90 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $368.20 | 2022-2025 | Qulipta, Ubrelvy, Botox |
| Lilly USA, LLC | $90.92 | 2019-2025 | Amyvid, Kisunla |
| Sk Life Science, INC. | $84.60 | 2021-2024 | |
| Emd Serono, INC. | $76.01 | 2019-2025 | |
| Neurocrine Biosciences, INC. | $60.34 | 2019-2022 | |
| E.R. Squibb & Sons, L.L.C. | $59.85 | 2020-2022 | |
| Novartis Pharmaceuticals Corporation | $59.72 | 2019-2024 | |
| Argenx US, INC. | $58.76 | 2023-2025 | Vyvgart, Vyvgart Hytrulo |
| Janssen Pharmaceuticals, INC | $55.25 | 2021-2025 | |
| Amneal Pharmaceuticals LLC | $52.08 | 2022-2023 | Rytary |
| Genentech USA, INC. | $51.61 | 2019-2025 | Enspryng |
| Sunovion Pharmaceuticals INC. | $45.15 | 2020-2021 | |
| Allergan, INC. | $41.28 | 2019-2022 | |
| Pfizer INC. | $41.14 | 2021-2025 | |
| Alexion Pharmaceuticals, INC. | $37.46 | 2019 |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biogen, INC. | $34.98 | 2022-2025 | Skyclarys |
| Celgene Corporation | $34.69 | 2023-2025 | Zeposia |
| Csl Behring | $26.58 | 2019-2020 | |
| Ucb, INC. | $25.13 | 2019 | |
| Eisai INC. | $23.95 | 2024 | |
| Astrazeneca Pharmaceuticals Lp | $21.36 | 2025 | Wainua |
| Amgen INC. | $21.13 | 2019 | |
| Cycle Pharmaceuticals INC | $20.51 | 2025 | Bafiertam, Tascenso Odt |
| Teva Pharmaceuticals USA, INC. | $20.18 | 2024 | Ajovy |
| Aucta Pharmaceuticals, INC. | $19.20 | 2024 | Motpoly Xr |
| Otsuka America Pharmaceutical, INC. | $17.98 | 2025 | Rexulti |
| Lundbeck LLC | $17.86 | 2021 | |
| Kyowa Kirin, INC. | $16.45 | 2021 | |
| Medtronic USA, INC. | $15.48 | 2019 | |
| Neurelis, INC. | $14.60 | 2021 | |
| Livanova USA, INC. | $13.51 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Ward listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.